Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001246068 | SCV001419401 | likely benign | Nemaline myopathy 2 | 2023-11-10 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002222685 | SCV002500802 | uncertain significance | not specified | 2022-03-31 | criteria provided, single submitter | clinical testing | Variant summary: NEB c.23815C>T (p.Arg7939Cys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.8e-05 in 249142 control chromosomes (gnomAD). This frequency is not higher than expected for a pathogenic variant in NEB causing Nemaline Myopathy 2 (4.8e-05 vs 0.0035), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.23815C>T in individuals affected with Nemaline Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Breakthrough Genomics, |
RCV004692326 | SCV005187933 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001246068 | SCV002084003 | uncertain significance | Nemaline myopathy 2 | 2020-02-13 | no assertion criteria provided | clinical testing |